UCB (OTCMKTS:UCBJF) Shares Gap Down – Here’s Why

UCB SA (OTCMKTS:UCBJF)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $265.96, but opened at $242.66. UCB shares last traded at $246.0250, with a volume of 176 shares trading hands.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a report on Monday, October 6th. Morgan Stanley reiterated an “overweight” rating on shares of UCB in a report on Monday, September 8th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy”.

UCB Trading Down 1.0%

The firm has a 50-day simple moving average of $267.01 and a 200-day simple moving average of $218.10. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.